COPENHAGEN, December 12 /PRNewswire/ --

- Summary: An IND has Been Filed With the FDA for the Fourth Genmab
Antibody Developed Under the Company's Collaboration With Roche.

Genmab A/S (OMX: GEN) announced today that an Investigational New Drug
application (IND) for a Genmab antibody developed under the company's
collaboration with Roche has been filed with the FDA by Roche. Genentech and
Roche are collaborating on development of the antibody which selectively
blocks the interaction of the OX40 ligand and its receptor. The companies are
evaluating the antibody for the treatment of asthma. Genmab will receive a
milestone payment from Roche which does not influence Genmab's financial
guidance for 2007.

In pre-clinical data published in a recent article and commentary in The
Journal of Clinical Investigation, treatment with the human OX40L blocking
antibody led to significant therapeutic effects in a nonhuman primate model
of allergic inflammation. The mechanisms of action of the human antibody
include effective blockade of OX40L binding to its receptor, and depletion of
cells expressing OX40L. Depletion of OX40L-expressing cells was shown to
depend on interaction of immune effector cells with the therapeutic antibody.
The observed in vivo efficacy of the OX40L-specific antibody may also involve
restoration of peripheral tolerance mechanisms. Breaking of tolerance
promotes development of autoimmune and allergic diseases.

Under the agreement with Roche, Genmab utilizes its broad antibody
expertise and development capabilities to create human antibodies to a broad
range of disease targets identified by Roche. Genmab receives milestone and
royalty payments based on successful products. In certain circumstances,
Genmab may obtain rights to develop products based on disease targets
identified by Roche.

"Four of the antibodies developed by Genmab under our collaboration with
Roche have now entered the clinic. We believe this achievement is a testament
to the skill of Genmab's pre-clinical development team who work carefully to
select the best product candidates and Roche's dedicated focus on progressing
them to market," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of
Genmab.

About Genmab A/S

Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery and
development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future, we
remain committed to our primary goal of improving the lives of patients who
are in urgent need of new treatment options.

For more information on Genmab's products and technology,
visit http://www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM);
HuMax-CD38(TM); and UniBody(R) are all trademarks of Genmab A/S.